Our awarded work (Poster Finalist at MSACL Europe, also see the PDF Poster Hemoglobinopathies_MSACL) on hemoglobinopathies and thalassemias
is now starting into a prospective study in cooperation with the University Medical Center Hamburg-Eppendorf, Germany.
The established high-throughput assay is focused on the identification of the most clinically relevant hemoglobin variants such as Hb S (sickle cell anemia, SCD) in homozygous or in heterozygous form combined with the Hb variants (e.g. Hb -C, -D, and -E).
Due to the increasing carrier-frequencies in the European Union, especially in urban areas (e.g. Berlin 1 birth in 2500 newborns), a fast, robust, and reliable assay is of great interest and these requirements are easily fulfilled by our developed high-resolution mass spectrometer (HRMS) assay.